Prices are closing data as of 2026-11-04, not real-time quotes. HK P/E and P/B multiples come from Eastmoney HK key statistics. Metric definitions: P/E, P/B, ROE.
Want the full AI research report for CONSUN PHARMA?
This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.
New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.
10-Year FinancialsFY2016–2025
Financial statements are reported in CNY, while share price and market cap are quoted in HKD.
Key Multi-Year Facts
- Revenue moved from CN¥1.22B in FY2016 to CN¥3.42B in FY2025 (9-year CAGR +12.1%).
- Profitable in every fiscal year across 2016–2025.
Latest 5 Fiscal Years
| Fiscal Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue (CNY B) | 2.04 | 2.34 | 2.59 | 2.97 | 3.42 |
| YoY | 16.6% | 14.4% | 10.7% | 14.6% | 15.2% |
| Net Income (CNY B) | 0.59 | 0.68 | 0.78 | 0.91 | 1.08 |
| YoY | 18.3% | 15.7% | 14.9% | 16.1% | 18.4% |
| Operating Cash Flow (CNY B) | 0.73 | 0.95 | 0.82 | 1.09 | 1.21 |
| ROE | 24.4% | 23.7% | 23.2% | 23.6% | 25.0% |
| Gross Margin | 74.7% | 75.3% | 74.2% | 75.6% | 78.0% |
| Net Margin | 28.9% | 29.2% | 30.3% | 30.7% | 31.5% |
| Debt-to-Assets | 33.3% | 29.7% | 28.9% | 24.9% | 24.5% |
Show all 10 fiscal years
| Fiscal Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (CNY B) | 1.22 | 1.66 | 1.84 | 1.73 | 1.75 | 2.04 | 2.34 | 2.59 | 2.97 | 3.42 |
| YoY | — | 35.7% | 11.1% | -6.3% | 1.4% | 16.6% | 14.4% | 10.7% | 14.6% | 15.2% |
| Net Income (CNY B) | 0.31 | 0.40 | 0.47 | 0.08 | 0.50 | 0.59 | 0.68 | 0.78 | 0.91 | 1.08 |
| YoY | — | 28.8% | 17.4% | -82.8% | 524.9% | 18.3% | 15.7% | 14.9% | 16.1% | 18.4% |
| Operating Cash Flow (CNY B) | 0.45 | 0.25 | 0.75 | 0.38 | 0.87 | 0.73 | 0.95 | 0.82 | 1.09 | 1.21 |
| ROE | 17.5% | 22.6% | 23.8% | 3.8% | 23.7% | 24.4% | 23.7% | 23.2% | 23.6% | 25.0% |
| Gross Margin | 74.5% | 74.0% | 75.1% | 73.0% | 75.4% | 74.7% | 75.3% | 74.2% | 75.6% | 78.0% |
| Net Margin | 25.1% | 23.9% | 25.2% | 4.6% | 28.5% | 28.9% | 29.2% | 30.3% | 30.7% | 31.5% |
| Debt-to-Assets | 25.3% | 42.2% | 35.9% | — | 36.3% | 33.3% | 29.7% | 28.9% | 24.9% | 24.5% |
Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: HKEX / Eastmoney financial statements, compiled mechanically without AI. Official filings
Risk ChecklistAs of 2026-11-05
Rules-based screening using HK financial statements and HKEX announcement categories (no AI opinions).
Checked across financial quality, solvency, going concern, and HKEX announcements (modified audit opinion, profit warning, suspension, auditor change) with no alerts or watch items triggered.
An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.
Dividends
Trailing 12-month dividend: HK$0.786 per share, or 5.02% yield at closing price; last full fiscal year: HK$0.740 (payout ratio 49.0%).
Figures are gross HKD per share before applicable withholding or Stock Connect dividend taxes.
More data: All research reports · Sector leaders · Market hours & holidays.
Compiled mechanically from public filings and market quotes (data as of 2026-11-05). For informational purposes only, not investment advice.